Dermapharm Holding SE (DMP) — Capital Reinvestment Ratio

Latest as of December 2025: 0.13x

Dermapharm Holding SE (DMP) has a Capital Reinvestment Ratio of 0.13x as of December 2025, meaning it reinvests 0% of its operating cash flow (€92.40 Million) in capital expenditures (€11.88 Million). See DMP equity to assets ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.13x
Capex / Operating Cash Flow

Operating Cash Flow

€92.40 Million
EUR

Capital Expenditures

€11.88 Million
EUR

Data as of

Dec 2025
Most recent filing

Dermapharm Holding SE Capital Reinvestment Ratio (2014–2025)

This chart tracks Dermapharm Holding SE's Capital Reinvestment Ratio across 12 annual periods. Check total reinvestment intensity of Dermapharm Holding SE to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Dermapharm Holding SE (2014–2025)

Year-by-year Capital Reinvestment Ratio for Dermapharm Holding SE from 2014 to 2025. For live market cap and broader valuation context, see Dermapharm Holding SE market capitalisation.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2025 0.23x €181.51 Million €42.12 Million ▲ +22.2%
2024 0.19x €201.38 Million €38.24 Million ▲ +0.3%
2023 0.19x €219.42 Million €41.54 Million ▲ +40.0%
2022 0.14x €288.53 Million €39.01 Million ▼ -44.7%
2021 0.24x €250.37 Million €61.20 Million ▼ -21.4%
2020 0.31x €131.10 Million €40.80 Million ▼ -32.6%
2019 0.46x €100.61 Million €46.44 Million ▲ +182.8%
2018 0.16x €159.13 Million €25.97 Million ▼ -81.1%
2017 0.86x €86.74 Million €74.72 Million ▲ +272.4%
2016 0.23x €76.78 Million €17.76 Million ▼ -37.5%
2015 0.37x €40.38 Million €14.93 Million ▼ -29.4%
2014 0.52x €54.26 Million €28.42 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow